赛德萨阿糖胞苷CYTOSAR

[Indications of Cedesa cytarabine] All kinds of acute leukemia, non-Hodgkin’s lymphoma, bone marrow transplantation pretreatment, leukemia brain metastasis.

【 Usage and Dosage 】 Dosage and usage vary according to different chemotherapy schemes, and can be given by intravenous infusion or injection, subcutaneous injection or intrathecal injection, but oral administration is ineffective. Induction and remission of acute myeloid leukemia is generally given 100-200 mg/m2/ day, continuous intravenous drip for 7 days. After remission, the middle dose can be 300-500 mg/m2/ day; Or a large dose of 1-3 g/m2, once every 12 hours for 3-5 days. The treatment of central nervous system leukemia by intrathecal injection is 5-75 mg/m2, and 30 mg/m2 is generally appropriate. Once every 4 days until the cerebrospinal fluid returns to normal. Sheath injection can be prepared with 0.9% sodium chloride without preservatives and used immediately.

[Adverse reactions of cytosar of Cedesa cytarabine] Bone marrow suppression, nausea, vomiting, liver and kidney dysfunction, oral inflammation or ulcer, thrombophlebitis, fever, occasional abdominal pain, anorexia, gastrointestinal bleeding, sepsis, cellulitis at the injection site, pneumonia, neuritis or nerve damage, rash, freckles, skin and mucous membrane bleeding, chest pain, joint pain, throat.

【 Precautions 】 When drugs lead to bone marrow suppression, when the number of platelets is less than 50000/m3 or polymorphonuclear granulocytes is less than 1000/m3, it is necessary to stop taking drugs or change the therapy. After stopping taking drugs, the peripheral blood components may continue to decrease until they reach the minimum after 5-7 days of stopping taking drugs. When there is a clear phenomenon of bone marrow recovery, medication can be restarted. Patients with poor liver function should use less. Regularly check liver and kidney function and serum uric acid concentration.

[Contraindication of cytosar in Cedesa] Patients with drug-induced myelosuppression.

[Pharmacology and Toxicology] Aracytarabine is a synthetic nucleoside, which differs from general nucleosides such as cytosine nucleoside and deoxycytosine nucleoside in that it is a sugar part. This drug is arabinose instead of ribose or deoxyribose. In tissue culture, it is cytotoxic to various proliferative mammalian cells. It can inhibit cell growth, but has no effect on resting KB cells at high concentration. Its basic function is to inhibit the synthesis of deoxycytosine nucleoside, but also inhibit cytosine nucleotide kinase and its incorporation into nucleic acid, thus inhibiting cells and hurting cells. In vivo anti-tumor experiments confirmed that this drug inhibited different tumors transplanted into mice in the dosage range of 3-50 mg/kg/ day, mainly affecting the DNA synthesis of dividing cells, and acting jointly on reproductive time and DNA synthesis period. The drug also has immunosuppression, which is manifested in inhibiting the synthesis of hemagglutinin in mice.

[Medication for pregnant women and breast-feeding] This medicine has teratogenic effect on some animals. Pregnant or possibly pregnant women should weigh the advantages and disadvantages before taking it. Breast-feeding women should stop breastfeeding when taking medicine.

[Drug overdose] There is no antidote for this product overdose. Intravenous drip of 4.5g/m2 for more than 1 hour, once every 12 hours, for a total of 12 times, has caused irreversible increase of central nervous system toxicity and death.

[Storage] Shaded, sealed and kept in a cold place.